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We conducted a case–control study to investigate risk 
factors for multidrug-resistant tuberculosis (MDR TB) in the 
People’s Republic of China. Genotyping analysis was used 
to estimate the percentage of cases from recent transmission 
among 100 MDR TB case-patients hospitalized during April 
2007–July 2009. Molecular subtyping of isolates showed 
that 41% of MDR TB strains clustered. Beijing genotype 
was found in 94% of the MDR TB isolates and 79% of the 
pan-susceptible isolates. In multivariate analysis, MDR 
TB was independently associated with Beijing genotype, 
retreatment for TB, symptoms lasting >3 months before 
fi rst evaluation at the hospital, lack of health insurance, 
and being a farmer (vs. being a student). MDR TB was 
associated with Beijing genotype and lower socioeconomic 
status. A large percentage of MDR TB cases seemed to 
result from recent transmission. Early detection, effective 
treatment, and infection control measures for MDR TB are 
needed to reduce transmission.
Multidrug-resistant tuberculosis (MDR TB), defi ned as resistance to at least isoniazid and rifampin, has 
emerged as a global public health problem (1). The People’s 
Republic of China has the second greatest number of MDR 
TB cases in the world (2). According to the National 
Anti-Tuberculosis Drug Resistance Survey in 2007, an 
estimated 120,000 new MDR TB cases emerge annually 
in China, accounting for ≈24% of MDR TB worldwide 
(3). Although MDR TB represents only 8% of incident 
TB cases in China, controlling MDR TB is challenging 
because it is diffi cult to diagnose and treat (4). Thus, MDR 
TB is increasingly becoming a serious threat to TB control 
(3,5), and the recognition of extensively drug-resistant TB 
has furthered highlighted this threat (6,7).
The fi rst pilot sites for the programmatic management 
of drug-resistant TB in China were established in October 
2006. By the end of July 2010, similar management 
programs covered 41 prefectures/cities in 12 provinces in 
which ≈1,000 patients with MDR TB were treated with 
standardized treatment regimens recommended by the 
World Health Organization (8,9).
Mycobacterium tuberculosis acquires resistance to 
antimicrobial drugs through the selection of bacteria with 
mutations in resistance genes (10). Particular resistance 
genotypes, such as isoniazid-resistant strains from which 
the katG gene has been deleted, have been associated 
with decreased growth and persistence of M. tuberculosis 
in mice and guinea pigs (11). A recent molecular study 
suggests that drug-resistant strains of M. tuberculosis may 
be as transmissible as pan-sensitive strains (12). However, 
some isoniazid-resistant strains, such as those with a 
mutation at aa 315 of the katG gene, were as transmissible 
as drug-susceptible strains; these resistant, but equivalently 
transmissible, strains are typically associated with 
outbreaks (13–15).
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In the past decade, many studies have evaluated the 
role of the Beijing genotype of M. tuberculosis in the 
worldwide TB epidemic (16,17). Beijing genotype strains 
are emerging in Southeast Asia, former Soviet republics, 
the Baltic states, and South Africa and are associated with 
multidrug resistance (17–22). In Europe, during 2003–
2006, about half of MDR TB and extensively drug-resistant 
TB cases were caused by recent transmission, and 85% 
of those cases were caused by Beijing strains; during the 
same period, only 6%–7% of drug-susceptible TB cases 
in Europe were caused by Beijing strains (21,22). As the 
name suggests, Beijing genotype strains are particularly 
prevalent in China. In a survey of 10 provinces in China, 
the average percentage of Beijing genotype strains was 
73%, but the percentage varied substantially by region, 
with the highest (93%) in the Beijing region (23).
Genotyping studies help elucidate transmission 
of TB by specifi c strains (17–20). Since 1993, IS6110 
restriction fragment-length polymorphism typing has 
been considered the standard for studying the molecular 
epidemiology of TB (24). Although restriction fragment-
length polymorphism typing has brought signifi cant new 
insights into TB transmission, the method is technically 
demanding and time-consuming (23). Therefore, a new 
standard typing method using mycobacterial interspersed 
repetitive unit–variable-number of tandem repeats (MIRU-
VNTR) in the genome was recently proposed for studying 
clustering and transmission (25). The analysis of regions of 
difference (RDs) in the genome of M. tuberculosis complex 
can be used to study the phylogeny of these bacteria; this 
approach can also be used as an alternative to the more 
complicated spoligotyping method for Beijing genotype 
strain identifi cation (26,27).
We used the RD105 deletion detection method to 
identify Beijing genotype strains. We also used 24-locus 
VNTR typing to investigate MDR TB transmission in 
patients admitted to the largest TB hospital in Shandong 
Province during April 2007–July 2009. Our goal was to 
characterize the genotypes of different MDR TB strains 
and identify specifi c risk factors associated with MDR TB 
and MDR TB strain clustering. A study in TB patients in 
the same hospital during 2004–2007 showed a prevalence 
of MDR TB of 10.8% (28). Although the national guideline 
of the TB control program requests directly observed 
treatment, in which TB patients take all doses under 
supervision, another study in rural Shandong showed that 
most TB patients do not receive directly observed treatment 
(29), which poses a risk for drug resistance. In Shandong 
Province, the programmatic management of drug-resistant 
TB has been introduced only in 1 prefecture, starting in 
October 2008.
Methods
Sampling Method
We conducted a case–control study at Shandong 
Provincial Tuberculosis Hospital (SPTH). We studied 
all 100 MDR TB patients and 97 patients infected with 
pan-sensitive TB strains who were admitted during April 
2007–July 2009. The patients with pan-sensitive TB 
were randomly selected from an electronic database with 
information on 974 hospitalized patients. According to 
the national reporting system, ≈10% of all TB cases are 
reported by specialized TB hospitals.
Data Collection
We obtained the following information from medical 
records for all study patients: sex, age, occupation, history 
of close contact with a TB patient (defi ned as a household 
member or colleague with TB), health insurance, TB 
treatment history, symptom duration before fi rst evaluation 
at SPTH, presence of cavities on chest radiographs, current 
alcohol use, current smoking, sputum smear test results, 
and HIV status. During the study period, all enrolled 
patients were admitted to the hospital 1 time only, and the 
average admission time was ≈1 month.
Drug Susceptibility Testing
Sputum samples from all hospitalized TB patients in 
SPTH were collected before the start of TB therapy and 
then cultured on Lowenstein-Jensen culture medium. 
M. tuberculosis complex was identifi ed by culturing on 
Lowenstein-Jensen medium containing p-nitrobenzoic 
acid, where growth indicates that the bacilli are not part of 
the M. tuberculosis complex. Isolates from all patients with 
M. tuberculosis–positive culture results were subjected to 
drug susceptibility testing. The fi rst-line drugs isoniazid, 
rifampin, streptomycin, and ethambutol were tested for 
drug susceptibility on the basis of the previously described 
proportion method (30). External quality assurance on drug 
susceptibility testing by profi ciency testing is conducted 
regularly by the national reference laboratory of China and 
the supranational reference laboratory of the Public Health 
Laboratory, Hong Kong Special Administrative Region, 
China. In addition, results of drug susceptibility testing of 
study samples were rechecked by the national reference 
laboratory.
DNA Extraction and Identifi cation 
of Beijing Genotype TB Strain
DNA was extracted according to standard methods 
(31). The Beijing genotype TB strain was identifi ed by 
using deletion-targeted multiplex PCR to detect the RD105 
deletion (26,27). Primers were synthesized according to a 
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study by Brosch et al. (26). The upstream primer used was 
5′-GGAGTCGTTGAGGGTGTTCAGCTCAGCTCAG
TC-3′; the 2 different downstream primers used were 
5′-CGCCAAGGCCGCATAGTCACGGTCG-3′ and 5′-
GGTTGCCCACTGGTCGATATGGTGGACTT-3′. An 
amplifi ed sequence length of 761 bp corresponded to a 
Beijing genotype strain, and a sequence length of 1,466 bp 
corresponded to a non-Beijing genotype.
The reaction system comprised 1 μL each of upstream 
and downstream primer (0.4 μmol/L), 5 μL of 2× Taq PCR 
MasterMix (Tiangen Biotech [Beijing] Co., Ltd., Beijing, 
China), and 2 ng of DNA template with suffi cient double-
distilled water added to bring the fi nal volume to 10 μL. 
Thirty-fi ve cycles were applied in the PCR in the following 
manner. Each cycle consisted of denaturation at 95°C for 5 
min, denaturation at 94°C for 30 s, annealing at 65°C for 30 
s, followed by 72°C for 30 s, and then extension at 72°C for 
7 min, after which products were stored at 4°C.
Amplifi cation products were analyzed by using 1% 
agarose gel, stained by 1 μg/mL ethidium bromide in 1× 
TrIS-borate-EDTA electrophoresis buffer. The standard 
strain H37Rv was used as a control, and we used a 100-
bp DNA ladder (Takara Biotechnology [Dalian] Co., Ltd., 
Dalian, China) for distinguishing molecular sizes.
Genotyping
For genotyping, we used the 24-loci MIRU-VNTR 
method, as recommended by Supply et al. (25). Primers 
were designed as described (25) and synthesized by 
Shanghai Sangon Biological Engineering Technology 
and Service Co., Ltd. (Shanghai, China). Each PCR was 
performed with 2 ng of template DNA in a 20-μL fi nal 
volume composed of 10 μL 2× PCR Master Mix (Tiangen 
Biotech [Beijing] Co., Ltd), 1 μL of each primer (fi nal 
concentration 0.4 μmol/L), and 8 μL of distilled water.
Thermal cycling consisted of the fi rst denaturation step 
at 95°C for 5 min, followed by 40 cycles of denaturation at 
94°C for 50 s, annealing at 65°C for 50 s, and extension at 
72°C for 1 min, with a fi nal extension at 72°C for 5 min. 
PCR products were stored at 4°C before further analysis.
PCR products were analyzed by electrophoresis on 
1% agarose gels after staining with ethidium bromide (1 
μg/mL). The sizes of the products were determined by 
using a gel imager with a 100-bp DNA ladder (Takara) 
as a reference. The number of repeats at each locus was 
calculated in relation to the size of the locus. H37Rv was 
used as reference.
Statistical Analyses
BioNumerics version 5.0 (Applied Maths, Inc., Sint-
Martens-Latern, Belgium) was used to perform clustering 
and phylogenetic tree analyses. The allelic diversity of each 
VNTR loci (h) and the discriminating power according 
to the Hunter-Gaston index were calculated by using the 
algorithm shown in Figure 1.
Logistic regression analysis was done to compare 
MDR TB case-patients with pan-sensitive TB case-
patients and to identify factors associated with clustering 
among MDR TB case-patients. We included the following 
variables in bivariate analysis: sex, age, occupation, history 
of close contact with a TB patient, health insurance, TB 
treatment history, symptom duration before fi rst evaluation 
in SPTH, presence of cavity on chest radiograph, current 
alcohol use, current smoking, diagnostic sputum smear test 
results, HIV status, and Beijing genotype. Variables with a 
p value <0.2 were included in multivariable analyses. The 
fi nal model was established by backward selection based 
on the fi t of the model as tested with the likelihood ratio χ2 
test (p = 0.05). All statistical analyses were performed by 
using SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA).
Ethical Issues
This research project was approved by the Chinese 
Ethical Committee for TB Operational Research, Chinese 
Center for Disease Control and Prevention, and SPTH. 
Patients were asked for written informed consent before 
drug susceptibility testing and genotyping were performed. 
Patients and TB hospitals were informed of test results, 
and the treatment regimen for each patient was adjusted 
according to the detected resistance profi les.
Results
Among the 1,530 M. tuberculosis isolates from all 
hospitalized patients during the study period, 556 (36.3%) 
were resistant to >1 fi rst-line drugs (isoniazid, rifampin, 
streptomycin, or ethambutol), of which 313 (20.5%) were 
resistant to 1 drug, 143 (9.3%) were resistant to >1 drug but 
were not MDR (poly-drug resistant), and 100 (6.5%) were 
MDR. A total of 33 of the 100 MDR TB patients and 47 of 
the 97 patients with pan-sensitive TB were from Jinan city, 
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Figure 1. The allelic diversity of each VNTR loci (h) and the 
discriminating power according to the Hunter-Gaston index 
(HGI) were calculated by using this algorithm (32). MIRU-VNTR, 
mycobacterial interspersed repetitive unit–variable number of 
tandem repeats; xi, the frequency of allele i; n, total no. of strains in 
the scheme; N, total number of strains in the typing scheme; s, total 
no. of different MIRU-VNTR patterns, nj, no. of strains belonging to 
the jth type.
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the capital of Shandong Province; other patients were from 
other parts of Shandong Province. The 97 selected controls 
were comparable to all patients with pan-sensitive TB with 
regard to potential confounding variables, such as age (38 
vs. 37 years, p = 0.79), sex (69.1% vs. 70.0% male, p = 
0.83), and retreatment (7.2% vs. 7.6%, p = 0.89).
Genotyping Characteristics
The RD105 deletion test identifi ed 94 of the 100 MDR 
TB strains and 77 (79%) of the 97 pan-sensitive strains as 
Beijing genotype strains (χ2 = 9.19, p = 0.002). Among 24 
loci, MIRU-VNTR, QUB11b, Mtub21, and Mtub4 showed 
high allelic diversity (h>0.60), and MIRU26, QUB26, 
MIRU31, MIRU10, Mtub39, QUB4156, MIRU39, and 
ETR-A showed middle allelic diversity (h>0.30) (Table 1).
We identifi ed 73 different MIRU-VNTR genotype 
profi les among the 100 MDR TB strains, comprising 59 
unique strains and 41 strains in 14 clusters; thus, 41% of the 
MDR TB cases clustered. The number of isolates in DNA 
fi ngerprint clusters ranged from 2 to 6. The discriminating 
power according to the Hunter-Gaston index method was 
0.989. Dendrograms of 100 MDR TB cases, which were 
analyzed by using the RD105 deletion test and the MIRU-
VNTR method, are shown in Figure 2. No clustering was 
detected among non–Beijing genotype cases.
Determinants for Clustering among MDR TB Cases
In multivariate analysis comparing the 41 clustered 
MDR TB cases with the 59 nonclustered cases, we found 
that clustering was more likely to occur in isolates from 
patients who were <45 years of age (32 [50%] of 64) 
(adjusted odds ratio [OR] 3.5, 95% confi dence interval 
[CI] 1.4–9.0), never previously treated (23 [51%] of 45; 
adjusted OR 2.6, 95% CI 1.1–6.2), and infected with 
Beijing genotype strains (41 of 100). Because the non–
Beijing genotype strains did not include MDR TB strains, 
we did not calculate an OR.
Determinants for MDR TB
Sixty-one percent of MDR TB case-patients were 
male; 49% were <35 years of age, and 55% were 
receiving retreatment for TB (Table 2). In bivariate 
analysis, MDR TB was not signifi cantly associated 
with current alcohol use, current smoking, diagnostic 
sputum smear test results, or HIV status (tested patients 
all had negative results). Occupation, health insurance, 
TB treatment history, symptom duration before fi rst 
evaluation in SPTH, cavity on chest radiographs, and 
genotype strain were signifi cantly associated with MDR 
TB (p<0.05) (Table 2). Several of these factors remained 
signifi cant in multivariate analysis, including previous TB 
treatment (adjusted OR 12.0, 95% CI 4.5–31.8), history 
of TB symptoms for >3 months before fi rst visit to SPTH 
(adjusted OR 3.0, 95% CI 1.0–9.2), and lack of health 
insurance (adjusted OR 2.4, 95% CI 1.1–5.1). MDR TB 
occurred less frequently in students (adjusted OR 0.2, 
95% CI 0.1–0.7) than farmers. MDR TB cases were also 
more likely to be caused by a Beijing genotype TB strain 
(adjusted OR 4.3, 95% CI 1.4–13.9).
Discussion
In this study in Shandong Province, the fact that 45% 
of new TB cases are MDR TB and the high percentage 
of clustering among isolates (51%) indicate substantial 
MDR TB transmission. The percentage of case clustering 
among persons previously treated for MDR TB was also 
substantial (33%). Thus, a large percentage of MDR TB 
cases in Shandong Province most likely were caused 
by recent transmission. Nosocomial transmission is not 
likely to explain the high percentage of clustering because 
sputum samples were obtained at hospital admission. 
MDR TB was more likely to be diagnosed in population 
groups of lower socioeconomic status, such as farmers, 
persons with low education level, and those without health 
insurance. These fi ndings suggest that the prevalence of 
MDR TB among TB case-patients may be poverty related; 
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Table 1. Allelic diversity and number of repeats among 197 TB 
isolates, Shandong Province, People’s Republic of China, April 
2007–July 2009* 
Locus† Allelic diversity Allele no. 
No. repeats, 
range 
QUB11b 0.703 6 1–7
Mtub21 0.642 7 1–7
Mtub4 0.621 5 1–5
MIRU26 0.595 8 3–11 
QUB26 0.551 9 2–10 
MIRU31 0.494 7 2–9
MIRU10 0.340 4 1–4
Mtub39 0.335 7 1–7
QUB4156 0.331 5 1–5
MIRU39 0.326 3 2–4
ETR-A 0.303 7 1–7
Mtub30 0.295 4 2–5
MIRU40 0.263 6 1–6
MIRU4 0.237 6 0–7
MIRU16 0.175 4 1–4
MIRU27 0.156 3 1–3
ETR-B 0.146 3 1–3
MIRU20 0.146 3 1–3
MIRU23 0.093 4 2–6
Mtub34 0.073 2 2–3
Mtub29 0.055 4 2–5
ETR-C 0.055 3 2–4
MIRU2 0.000 1 1
MIRU24 0.000 1 1
*Allelic diversity and number of repeats was determined by using a 24-
locus mycobacterial interspersed repetitive unit (MIRU)–variable-number 
of tandem repeats. TB, tuberculosis. 
†Loci are listed within each isolate group in descending order of allelic 
diversity.  
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therefore, these lower socioeconomic groups should be 
the highest priority for MDR TB prevention efforts.
Our molecular analysis found a high discriminative 
power for using 24-locus MIRU-VNTR genotyping. We 
found that 41% of MDR TB isolates shared identical 
VNTR profi les, and clusters of up to 6 cases in size were 
observed. In general, MDR TB has a low conversion rate 
and lengthy negative conversion period, given its high 
capacity for transmission (9). This phenomenon indicates 
that some MDR TB strains might give rise to widespread 
transmission of MDR TB.
Our genotyping analysis showed that strain clustering 
was more common among young patients, in new cases, 
and in TB caused by Beijing genotype strains. The fi nding 
regarding younger patients was in agreement with a 
previous study, suggesting that TB among young patients 
more frequently is clustered (33).
Most MDR TB cases occurred among patients who 
were previously treated, were less educated, lacked health 
insurance, or had a medical history of TB for >3 months 
before entering SPTH. Patients who have previously 
received treatment are at risk for MDR TB because of 
inadequate treatment of drug-sensitive TB or because of 
relapse after a previous episode of unrecognized MDR TB 
that was incorrectly treated as drug sensitive. Although 
reinfection also should always be considered (34), our 
fi ndings reaffi rm the need to prevent MDR TB through 
effective anti-TB drug regimens that are based on drug 
susceptibility profi les and are administered under direct 
supervision for the correct duration. Efforts are needed to 
strengthen basic TB diagnosis and treatment at the primary 
health care level, where such patients are likely to fi rst 
contact the health system.
Beijing genotype strains are more common in Asia, 
former Soviet republics, and South Africa, but they are 
spreading worldwide (35,36). Several studies have shown 
that these strains are prevalent in China, especially northern 
China (23). A previous study found that non-Beijing 
strains represent 20.6% of strains in Shandong Province 
(37). In our sample from Shandong Province, Beijing 
genotype strains constituted 94% of MDR TB and 80% 
of pan-sensitive cases, suggesting that Beijing genotype 
is associated with MDR TB phenotype. Drobniewski et al. 
suggested that these Beijing strains have greater virulence 
and transmissibility and a tendency toward generation of 
MDR TB, although the mechanism remains unclear (38).
Our study has 2 main limitations. First, patients in this 
study were recruited only from 1 large TB hospital. The 
clustering proportion will depend on the completeness of 
the sampling, in which increasing sampling fractions will 
identify more clustering (39,40). Thus, our results likely 
underestimate the percentage of clustering. Because no 
reliable estimates exist of the incidence and prevalence 
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Figure 2. Dendrogram of 100 multidrug-resistant tuberculosis cases 
analyzed by using the RD105 deletion test and the MIRU-VNTR 
method. RD, region of difference; MIRU-VNTR, mycobacterial 
interspersed repetitive unit–variable number of tandem repeats; B, 
Beijing family; NB, no Beijing family. Scale bar indicates nucleotide 
substitutions per site.
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of MDR TB in Shandong Province, we do not know 
the percentage of MDR TB case-patients who were 
hospitalized in the study hospital and thus cannot estimate 
the extent to which we underestimated the clustering 
percentage. Studying a larger, geographically defi ned 
population will help us better understand the transmission 
dynamics of MDR TB and further identify populations 
or settings that should be made a priority for MDR TB 
prevention. Second, we did not investigate epidemiologic 
links between patients, such as home, job site, community, 
or congregate settings.
MDR TB presents one of the major challenges in TB 
control in China (3,30). Our fi ndings of a relatively high 
prevalence of MDR TB among new TB cases and a high 
percentage of clustering among MDR TB cases show that 
MDR TB transmission is a large problem in Shandong 
Province, China, highlighting the risk for further occurrence 
of drug-resistant TB. The general programmatic management 
of MDR TB as well as specifi c measures are urgently needed 
to control transmission of MDR TB in China.
Our study highlights the challenges of controlling 
MDR TB in China. There is a trend toward lower risk 
for MDR TB in higher socioeconomic groups. The recent 
transmission of MDR TB may be contributing to a large 
percentage of cases. Without early diagnosis and effective 
treatment, these new cases will continue to generate 
further infections in the community. China must urgently 
scale up prevention of MDR TB through better infection 
control, enhancement of directly-observed treatments, 
universal use of appropriate diagnosis and treatment 
for MDR TB. Similarly, Beijing strains continue to 
predominate and to be associated with MDR TB, meaning 
that more dedicated research is needed to understand why 
these strains have survived and thrived in China, as well 
as other countries.
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Table 2. Risk factors for MDR TB, Shandong Province, People’s Republic of China, April 2007–July 2009* 
Patient data 
No. (%) patients with 
MDR TB, n = 100 
No. (%) patients with 
pan-sensitive TB, n = 97 Crude OR (95% CI) Adjusted OR† (95% CI) 
Sex
 M 61 (61.0) 67 (69.1) 1
 F 39 (39.0) 30 (30.9) 0.7 (0.4–1.3) 
Age group, y 
 15–34 49 (49.0) 56 (57.7) 1
 35–54 38 (38.0) 21 (21.6) 2.1 (1.1–4.0) 
 >55 13 (13.0) 20 (20.6) 0.7 (0.3–1.6) 
Occupation
 Farmer 39 (39.0) 29 (29.9) 1 1
 Blue-collar worker 16 (16.0) 12 (12.4) 1.0 (0.4–2.4) 0.8 (0.2–2.4) 
 White-collar worker 37 (37.0) 39 (40.2) 0.7 (0.4–1.4) 0.6 (0.3–1.4) 
 Student 8 (8.0) 17 (17.5) 0.4 (0.1–0.9) 0.2 (0.1–0.7) 
Close contact with TB patient 
 No 90 (90.0) 90 (92.8) 1
 Yes 10 (10.0) 7 (7.2) 0.7 (0.3–1.9) 
Health insurance 
 Yes 33 (33.0) 48 (49.5) 1 1
 No 67 (67.0) 49 (50.5) 2.0 (1.1–3.5) 2.4 (1.1–5.1) 
History of TB treatment 
 New case 45 (45.0) 90 (92.8) 1 1
 Retreatment case 55 (55.0) 7 (7.2) 15.7 (6.6–37.3) 12.0 (4.5–31.8) 
Symptom duration before first evaluation in Shandong Provincial TB Hospital, mo 
 <1 14 (14.0) 31 (32.0) 1 1
 1–2 16 (16.0) 30 (30.9) 1.2 (0.5–2.8) 1.3 (0.5–3.8) 
 3–5 14 (14.0) 17 (17.5) 1.8 (0.7–4.7) 3.0 (1.0–9.2) 
 >6 56 (56.0) 19 (19.6) 6.5 (2.9–14.8) 3.3 (1.2–9.1) 
Cavity visible on radiograph 
 No 55 (55.0) 67 (69.1) 1
 Yes 45 (45.0) 30 (30.9) 1.8 (1.0–3.3) 
Beijing genotype 
 No 6 (6.0) 20 (20.6) 1 1
 Yes 94 (94.0) 77 (79.4) 4.1 (1.6–10.6) 4.3 (1.4–13.9) 
*MDR TB, multidrug-resistant tuberculosis; OR, odds ratio; CI, confidence interval. 
†Adjusted for all other factors included in the multivariate model. 
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